Experience with Oritavancin therapy in invasive gram-positive infections

0

The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses” Stewart et al (2017).

Abstract:

INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited.

METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections.

RESULTS: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated.

CONCLUSION: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted.

Reference:

Stewart, C.L., Turner, M.S., Frens, J.J., Snider, C.B. and Smith, J.R. (2017) Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. Infectious Diseases and Therapy. April 6th. [Epub ahead of print].

doi: 10.1007/s40121-017-0156-z.

Thank you to our partners for supporting IVTEAM

Other stories

Loading…

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.